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Casein Kinase 1 Modulator  
PF-05251749
Circadian rhythm is regulated by the 
body’s inner central clock. This clock con-
trols key body functions, including wake/
sleep cycles, body temperature, digestion, 
hormonal cycles, and behavioural patterns. 
Patients afflicted with Parkinson disease of-
ten show symptoms of  a condition collec-
tively called irregular sleep wake rhythm dis-
order. Irregular sleep wake rhythm disorder 
is a circadian rhythm disorder where patients 
experience fragmented night-time sleep lead-
ing to daytime sleepiness, severe fatigue and 
difficulty with activities of  daily living. An-
other symptom associated with sleep-wake 
cycle is sundowning. It affects 20% or more 
patients diagnosed with Alzheimer’s disease, 
who become confused, anxious, aggressive, 
agitated or restless later in the day. It usually 
increases in frequency over the course of  the 
disease and disability progression [1].
Many drugs, primarily psychopharmaceu-
ticals, target one or more aspects of  the sleep-
wake cycle in order to normalise circadian 
rhythm, but still do so with quite a number of  
side effects or adverse reactions. Therefore, it 
comes as no surprise that fine-tuning of  the 
circadian rhythm emerged as an interesting 
research target. In light of  that fact, casein ki-
nase 1 modulators seem to be at the forefront 
of  that research, especially a compound, just 
known as PF-05251749. It is a regulator of  
the body’s inner clock, which is a part of  a 
group of  potential disease-modifying thera-
pies for Parkinson’s and Alzheimer’s diseases. 
Namely, a small region within the brain’s hy-
pothalamus - the suprachiasmatic nucleus is 
responsible for controlling circadian rhythms, 
and an enzyme called casein kinase 1 (CK1), 
which exists in two forms, is a key regulator 
of  this clock. CK1 epsilon and CK1 delta are 
closely related Ser-Thr protein kinases and 
the fact that they serve as key clock regula-
tors is demonstrated by dramatic alterations 
of  the circadian period in mammals with mu-
tations of  those proteins. Specifically, genetic 
ablation of  CK1 delta alters the length of  a 
single cycle of  sleep-wake, and loss of  CK1 
epsilon results in arrhythmicity.
Biogen Inc. recently acquired PF-
05251749 and will test it further in clinical 
trials as a treatment to correct irregular sleep 
wake rhythm disorder in Parkinson’s disease 
and sundowning in Alzheimer’s disease [2]. 
Pfizer Corporation primarily set to devel-
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op this compound for the treatment of  Al-
zheimer’s disease, but it was discontinued due 
to Pfizer’s ending of  its neurology research 
and development [3].
Investigated compound PF-05251749 is 
an oral, brain-penetrable, highly selective, 
inhibitor of  both forms of  CK1. Inhibit-
ing CK1 disrupts the function of  two genes, 
Circadian locomotor output cycles kaput 
(CLOCK) and Brain and Muscle ARNT-Like 
1 (BMAL1), which are thought to influence 
the regulation of  circadian rhythms [2]. The 
chemical structure of  the compound is yet 
not disclosed. PF-05251749 has previously 
demonstrated an acceptable safety profile in 
Phase Ia clinical studies. Those consisted of  
two Phase 1 clinical trials in healthy volun-
teers, aged 18 to 55 and 18 to 85. They were 
conducted to determine not only the safety 
of  PF-05251749 but also to assess pharma-
cokinetics and pharmacodynamics, as well 
as to find out how much of  the compound 
reaches the cerebrospinal fluid. Biogen Inc. 
aims to initiate a Phase Ib study in fourth-
quarter of  2020 [4,5]. 
Alzheimer’s disease and Parkinson’s dis-
ease are characterized with debilitating sleep 
disorders and agitation. Therefore, regulation 
of  the circadian rhythm might hold promise 
to addressing these behavioural and neuro-
logical symptoms. One of  major targets are 
CK1 modulators, as CK1 belongs to a large 
family of  protein kinases that function as 
regulators of  signal transduction pathways 
in most eukaryotic cell types. Different CK1 
inhibitors are currently in various stages of  
research, such as D4476, PF-670462, PF-
4800567 hydrochloride and others [6]. Since 
this is a drug class with a new mechanism of  
action, along with a significant clinical poten-
tial, we look forward to their further develop-
ment and research updates.
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